Detalhe da pesquisa
1.
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Lancet
; 403(10426): 533-544, 2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38310910
2.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
3.
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Lancet
; 397(10287): 1809-1818, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33964223
4.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
5.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
6.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306989
7.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
8.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
9.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702298
10.
Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens.
J Immunol
; 201(4): 1315-1326, 2018 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30006374
11.
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.
J Infect Dis
; 219(8): 1187-1197, 2019 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30407513
12.
Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.
Mol Ther
; 25(2): 547-559, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28153101
13.
Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
Infect Immun
; 85(3)2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28031267
14.
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.
Mol Ther
; 24(8): 1470-7, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27109630
15.
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
J Infect Dis
; 214(5): 772-81, 2016 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27307573
16.
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
J Infect Dis
; 211(7): 1076-86, 2015 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25336730
17.
Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
J Immunol
; 190(3): 1135-47, 2013 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23293353
18.
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
Mol Ther
; 22(11): 1992-2003, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24930599
19.
Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Immunology
; 141(4): 628-44, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24303947
20.
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Lancet Infect Dis
; 24(5): 465-475, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342107